ClinicalTrials.gg
CompletedNCT04916470STEP HFpEF DMUpdated Nov 2, 2026Results posted

Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes

A Phase 3 interventional study of Semaglutide and Placebo (Semaglutide) in Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 180 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Updated Nov 2, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
617
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 82 studies testing semaglutide in Diabetes Mellitus — 12 open to participants now, 14 under way, 2 of them phase 3. Semaglutide · Diabetes Mellitus.

Enrollment
16th of 82
617 · median 100
Started
2021
with 1 other
Phase 3
26 of 82
1 open now
Registered
63rd of 82
by date
Lead sponsor
63 of 82
Novo Nordisk A/S

Among the 82 studies testing semaglutide in Diabetes Mellitus, this one is the 16th largest by enrollment, is one of 2 that started in 2021, is one of 26 in phase 3, and was the 63rd registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

12 of the 82 studies testing semaglutide in Diabetes Mellitus are open now, in 8 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies testing semaglutide in Diabetes Mellitus, or all of them as a file.
02

Study summary

This study will look at how participants' daily life is affected by their heart failure. The study will also look at the change in participants' body weight.

This study will compare the effect of semaglutide (a new medicine) compared to "dummy" medicine on body weight and heart failure symptoms.

Participants will either get semaglutide or "dummy" medicine, which treatment participants get is decided by chance.

Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach area, thigh or upper arm.

During the study participants will have talks with the study staff about healthy lifestyle and physical activity.

The study will last for about 59 weeks, that is a little more than 1 year. Participants will have 12 clinic visits with the study doctor.

  • At 6 of the visits participants will have blood samples taken.
  • At 5 of the visits participants will be asked to fill in a questionnaire
  • At 4 of the visits participants will have to do a 6-minute walking test
  • At 3 of the visits participants will have a test to check the heart.
  • participants will have their eyes checked before or at the start of the study and at the end of the study

Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.

03

Conditions studied

  • Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, age above or equal to 18 years at the time of signing .
  • (BMI) greater than or equal to 30.0 kg/m\^2
  • (NYHA) Class II-IV
  • (LVEF) greater than or equal to 45% at screening
  • Diagnosed with T2D greater than or equal to 90 days prior to the day of screening
  • of below or equal to 10.0% as measured at the screening visit

Exclusion criteria

Exclusion Criteria:

  • A self-reported change in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days prior to screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
617 participants (actual)

Study arms

  • Experimental
    Semaglutide 2.4 mg once weekly (OW)

    Participants will receive semaglutide injections for 52 weeks.

    Drug: Semaglutide

  • Placebo comparator
    Semaglutide placebo OW

    Participants will receive semaglutide placebo injections for 52 weeks.

    Drug: Placebo (Semaglutide)

Interventions

  • Participants will receive semaglutide subcutaneous (s.c.; under the skin) injection(s) once-weekly for 52 weeks. Dose will be gradually increased to 2.4 mg: 0.25 mg from week 1 to 4, 0.5 mg from week 5 to 8, 1.0 mg from week 9 to 12, 1.7 mg from week 13 to 16 and 2.4 mg from week 17 to week 52.

  • DrugPlacebo (Semaglutide)

    Participants will receive semaglutide matching placebo s.c. injection(s) once-weekly for 52 weeks.

06

What researchers measure

Primary outcomes

  1. Change in KCCQ (Kansas City Cardiomyopathy Questionnaire) Clinical Summary Score

    Change in KCCQ-Clinical Summary Score (CSS) from baseline (week 0) to end of treatment (week 52) is presented. The KCCQ is a standardised 23-item, self-administered instrument that quantifies heart failure symptoms (frequency, severity, and recent change), physical limitation, quality of life (QOL), and social limitation. Scores were transformed to a range of 0 to 100 in which higher scores reflected better health status. KCCQ-Clinical Summary Score (CSS) included the symptom and physical limitation domains of the KCCQ. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).

    Time frame: Baseline (week 0), end of treatment (week 52)

  2. Percentage Change in Body Weight

    Percentage change in body weight from baseline (week 0) to end of treatment (week 52) is presented. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).

    Time frame: Baseline (week 0), end of treatment (week 52)

Secondary outcomes

  1. Change in Six-minute Walking Distance

    Change in six-minute walking distance from baseline (week 0) to end of treatment (week 52) is presented. The 6 Minute Walk Test is a direct and timed measure of walk distance. The goal is for the subject to walk as far as possible in six minutes without running. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).

    Time frame: Baseline (week 0), end of treatment (week 52)

  2. Hierarchical Composite Endpoint: Total Number of Wins for Each Treatment Group

    Hierarchical composite outcome measure from baseline (week 0) to end of trial (week 57) is presented. Analysis of the hierarchical composite endpoint was based on direct comparisons of each participant randomised to semaglutide 2.4 mg and placebo within each stratum. A 'treatment winner' (1000 imputations) based on similar observation time was declared based on endpoint hierarchy. Outcome data was evaluated based on in-trial observation period which was defined as time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death). Missing observations at week 52 for KCCQ-CSS and body weight were multiple (x1000) imputed (by MAR assumption) using available measurements at week 52 from participants of same randomized treatment arm. Missing observations due to CV death or previous HF event were single imputed using change from baseline to overall lowest KCCQ-CSS value across treatment arms and time points.

    Time frame: Baseline (week 0), end of trial (week 57)

  3. Change in C-Reactive Protein

    Change in C-Reactive Protein from baseline (week -2) to end of treatment (week 52) is presented. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).

    Time frame: From baseline (week -2) to end of treatment (week 52)

  4. Participants Achieving 10% Weight Loss or More (Yes/No)

    Participants achieving 10% weight loss or more (Yes/No) at week 52 is presented. In the reported data, 'Yes' infers number of participants who have achieved 10% weight loss or more whereas 'No' infers number of participants who have not achieved 10% weight loss or more. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).

    Time frame: At Week 52

  5. Participants Achieving 15% Weight Loss or More (Yes/No)

    Participants achieving 15% weight loss or more (Yes/No) at week 52 is presented. In the reported data, 'Yes' infers number of participants who have achieved 15% weight loss or more whereas 'No' infers number of participants who have not achieved 15% weight loss or more. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).

    Time frame: At Week 52

  6. Participants Achieving 20% Weight Loss or More (Yes/No)

    Participants achieving 20% weight loss or more (Yes/No) at week 52 is presented. In the reported data, 'Yes' infers number of participants who have achieved 20% weight loss or more whereas 'No' infers number of participants who have not achieved 20% weight loss or more. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).

    Time frame: At Week 52

  7. Participants Improving 5 Points or More in KCCQ Clinical Summary Score (Yes/No)

    Participants improving 5 points or more in KCCQ clinical summary score (Yes/No) at week 52 is presented. The KCCQ is a standardised 23-item, self-administered instrument that quantifies heart failure symptoms (frequency, severity, and recent change), physical limitation, quality of life (QOL), and social limitation. Scores were transformed to a range of 0 to 100 in which higher scores reflected better health status. KCCQ-CSS included the symptom and physical limitation domains of the KCCQ. In the reported data, 'Yes' infers number of participants who have improved 5 points or more in score whereas 'No' infers number of participants who have not improved 5 points or more in score. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).

    Time frame: At Week 52

  8. Participants Improving 10 Points or More in KCCQ Clinical Summary Score (Yes/No)

    Participants improving 10 points or more in KCCQ clinical summary score (Yes/No) at week 52 is presented. The KCCQ is a standardised 23-item, self-administered instrument that quantifies heart failure symptoms (frequency, severity, and recent change), physical limitation, quality of life (QOL), and social limitation. Scores were transformed to a range of 0 to 100 in which higher scores reflected better health status. KCCQ-CSS included the symptom and physical limitation domains of the KCCQ. In reported data, 'Yes' infers number of participants who have improved 10 points or more in score whereas 'No' infers number of participants who have not improved 10 points or more in score. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).

    Time frame: At Week 52

  9. Change in KCCQ Overall Summary Score

    Change in KCCQ overall summary score from baseline (week 0) to end of treatment (week 52) is presented. The KCCQ is a standardised 23-item, self-administered instrument that quantifies heart failure symptoms (frequency, severity, and recent change), physical limitation, QOL, and social limitation. Scores are transformed to a range of 0 to 100 in which higher scores reflect better health status. KCCQ- overall summary score (OSS) included the symptom, physical limitation, quality of life, and social limitation domains. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).

    Time frame: Baseline (week 0), end of treatment (week 52)

  10. Participants Achieving Threshold for Clinically Meaningful Within-participant Change in KCCQ-CSS (PGI-S)

    Participants achieving threshold for clinically meaningful within-participant change (based on participant perspective) in KCCQ-CSS (Patient Global Impression of Status \[PGI-S\]) at week 52 is presented. KCCQ is a standardised 23-item instrument that quantifies heart failure symptoms (frequency, severity, and recent change), physical limitation, QOL, and social limitation. Scores are transformed to a range of 0 to 100 where higher scores reflect better health status. KCCQ-CSS includes the symptom and physical limitation domains of KCCQ. PGI-S for KCCQ was used to rate participants' symptoms of heart failure in last two weeks using a 4-category ordinal scale (no symptoms, mild, moderate, severe). The threshold of 16.3 points is based on PGI-S for KCCQ-CSS. Outcome data was evaluated based on in-trial period. In-trial period was defined as time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).

    Time frame: At Week 52

  11. Participants Achieving Threshold for Clinically Meaningful Within-participant Change in Six Minute Walking Distance (6MWD) (PGI-S)

    Participants achieving threshold for clinically meaningful within-participant change in 6MWD (PGI-S) at week 52 is presented. The six minute walk test (6MWT) is a direct and timed measure of walk distance. The goal is for the subject to walk as far as possible in six minutes without running. The PGI-S for 6MWT was used to rate any difficulty that participants were experiencing in walking quickly using a 5-category ordinal scale (not at all difficult, a little difficult, moderately difficult, very difficult, or unable to walk quickly). The threshold of 16.2 meters is based on PGI-S for 6MWT. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).

    Time frame: At Week 52

  12. Change in Waist Circumference

    Change in waist circumference from baseline (week 0) to end of treatment (week 52) is presented. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).

    Time frame: From baseline (week 0) to end of treatment (week 52)

  13. Change in Systolic Blood Pressure

    Change in systolic blood pressure from baseline (week -2) to end of treatment (week 52) is presented. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).

    Time frame: Bseline (week -2), end of treatment (week 52)

  14. Change in Glycated Haemoglobin (HbA1c)

    Change in HbA1c from baseline (week 0) to end of treatment (week 52) is presented. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).

    Time frame: Baseline (week 0), end of treatment (week 52)

  15. Number of Treatment Emergent Severe or Clinically Significant Hypoglycaemia Episodes

    Number of treatment emergent severe or clinically significant hypoglycaemia episodes from baseline (week 0) to end of trial (week 57) is presented. Clinically significant hypoglycemic episode is defined as blood glucose concentration of less than 54 milligrams per deciliter (mg/dL) which is sufficiently low to indicate serious, clinically important hypoglycaemia. Severe hypoglycemic episode is defined as hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery. The outcome data was evaluated based on on-treatment period. A time-point was considered as 'on-treatment' if any dose of trial product had been administered within the prior 5 weeks (35 days).

    Time frame: From baseline (week 0) to end of trial (week 57)

07

Results

Posted Nov 2, 2026

Participant flow

The trial was conducted at 108 sites in 16 countries as follows (number of sites that screened participants/number of sites that randomised participants): Argentina (6/6), Austria (4/4), Canada (7/6), Czech Republic (4/4) Germany (7/7), Hungary (10/10), India (9/9), Israel (5/5), Italy (6/6), Japan (7/6), Netherlands (5/5), Poland (6/6), Spain (3/3), Sweden (2/2), United Kingdom (7/7) and United States (26/22).

Participant flow — Overall Study
MilestoneSemaglutide 2.4 mgPlacebo
Started310307
Full analysis set310306
Safety analysis set310306
Completed292291
Not completed1816
Withdrew: Withdrawal by subject54
Withdrew: Lost to follow-up72
Withdrew: Death610

Outcome measures

PrimaryChange in KCCQ (Kansas City Cardiomyopathy Questionnaire) Clinical Summary Score

Change in KCCQ-Clinical Summary Score (CSS) from baseline (week 0) to end of treatment (week 52) is presented. The KCCQ is a standardised 23-item, self-administered instrument that quantifies heart failure symptoms (frequency, severity, and recent change), physical limitation, quality of life (QOL), and social limitation. Scores were transformed to a range of 0 to 100 in which higher scores reflected better health status. KCCQ-Clinical Summary Score (CSS) included the symptom and physical limitation domains of the KCCQ. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).

Time frame:
Baseline (week 0), end of treatment (week 52)
Reported as:
Mean · Score on a scale
Change in KCCQ (Kansas City Cardiomyopathy Questionnaire) Clinical Summary Score
Score on a scaleSemaglutide 2.4 mgPlacebo
Change in KCCQ (Kansas City Cardiomyopathy Questionnaire) Clinical Summary Score14.4 ± 18.37.6 ± 18.8
Statistical analysis
  • Semaglutide 2.4 mg vs Placebo · ANCOVA · p = <0.0001 · Treatment difference: 7.3 · 95% CI 4.1 to 10.4
PrimaryPercentage Change in Body Weight

Percentage change in body weight from baseline (week 0) to end of treatment (week 52) is presented. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).

Time frame:
Baseline (week 0), end of treatment (week 52)
Reported as:
Mean · Percentage change in body weight
Percentage Change in Body Weight
Percentage change in body weightSemaglutide 2.4 mgPlacebo
Percentage Change in Body Weight-10.2 ± 6.8-3.2 ± 5.9
Statistical analysis
  • Semaglutide 2.4 mg vs Placebo · ANCOVA · p = <0.0001 · Treatment difference: -6.4 · 95% CI -7.6 to -5.2
SecondaryChange in Six-minute Walking Distance

Change in six-minute walking distance from baseline (week 0) to end of treatment (week 52) is presented. The 6 Minute Walk Test is a direct and timed measure of walk distance. The goal is for the subject to walk as far as possible in six minutes without running. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).

Time frame:
Baseline (week 0), end of treatment (week 52)
Reported as:
Mean · Meters
Change in Six-minute Walking Distance
MetersSemaglutide 2.4 mgPlacebo
Change in Six-minute Walking Distance16.9 ± 54.33.8 ± 49.8
SecondaryHierarchical Composite Endpoint: Total Number of Wins for Each Treatment Group

Hierarchical composite outcome measure from baseline (week 0) to end of trial (week 57) is presented. Analysis of the hierarchical composite endpoint was based on direct comparisons of each participant randomised to semaglutide 2.4 mg and placebo within each stratum. A 'treatment winner' (1000 imputations) based on similar observation time was declared based on endpoint hierarchy. Outcome data was evaluated based on in-trial observation period which was defined as time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death). Missing observations at week 52 for KCCQ-CSS and body weight were multiple (x1000) imputed (by MAR assumption) using available measurements at week 52 from participants of same randomized treatment arm. Missing observations due to CV death or previous HF event were single imputed using change from baseline to overall lowest KCCQ-CSS value across treatment arms and time points.

Time frame:
Baseline (week 0), end of trial (week 57)
Reported as:
Number · Number of wins
Hierarchical Composite Endpoint: Total Number of Wins for Each Treatment Group
Number of winsSemaglutide 2.4 mgPlacebo
Time to all-cause death27961814
Number of heart failure events44341171
Time to first heart failure event3426
Change in KCCQ-CSS greater than or equal to (>=)15 point difference3061817303
Change in KCCQ-CSS >=10 point difference62504763
Change in KCCQ-CSS >=5 point difference69255912
Change in six minute walking distance (6MWD) >=30 metre difference46073920
SecondaryChange in C-Reactive Protein

Change in C-Reactive Protein from baseline (week -2) to end of treatment (week 52) is presented. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).

Time frame:
From baseline (week -2) to end of treatment (week 52)
Reported as:
Geometric mean · Ratio to baseline of C-Reactive Protein
Change in C-Reactive Protein
Ratio to baseline of C-Reactive ProteinSemaglutide 2.4 mgPlacebo
Change in C-Reactive Protein0.58 ± 146.60.91 ± 128.4
SecondaryParticipants Achieving 10% Weight Loss or More (Yes/No)

Participants achieving 10% weight loss or more (Yes/No) at week 52 is presented. In the reported data, 'Yes' infers number of participants who have achieved 10% weight loss or more whereas 'No' infers number of participants who have not achieved 10% weight loss or more. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).

Time frame:
At Week 52
Reported as:
Count of participants · Participants
Participants Achieving 10% Weight Loss or More (Yes/No)
ParticipantsSemaglutide 2.4 mgPlacebo
Yes14729
No139249
SecondaryParticipants Achieving 15% Weight Loss or More (Yes/No)

Participants achieving 15% weight loss or more (Yes/No) at week 52 is presented. In the reported data, 'Yes' infers number of participants who have achieved 15% weight loss or more whereas 'No' infers number of participants who have not achieved 15% weight loss or more. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).

Time frame:
At Week 52
Reported as:
Count of participants · Participants
Participants Achieving 15% Weight Loss or More (Yes/No)
ParticipantsSemaglutide 2.4 mgPlacebo
Yes6411
No222267
SecondaryParticipants Achieving 20% Weight Loss or More (Yes/No)

Participants achieving 20% weight loss or more (Yes/No) at week 52 is presented. In the reported data, 'Yes' infers number of participants who have achieved 20% weight loss or more whereas 'No' infers number of participants who have not achieved 20% weight loss or more. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).

Time frame:
At Week 52
Reported as:
Count of participants · Participants
Participants Achieving 20% Weight Loss or More (Yes/No)
ParticipantsSemaglutide 2.4 mgPlacebo
Yes215
No265273
SecondaryParticipants Improving 5 Points or More in KCCQ Clinical Summary Score (Yes/No)

Participants improving 5 points or more in KCCQ clinical summary score (Yes/No) at week 52 is presented. The KCCQ is a standardised 23-item, self-administered instrument that quantifies heart failure symptoms (frequency, severity, and recent change), physical limitation, quality of life (QOL), and social limitation. Scores were transformed to a range of 0 to 100 in which higher scores reflected better health status. KCCQ-CSS included the symptom and physical limitation domains of the KCCQ. In the reported data, 'Yes' infers number of participants who have improved 5 points or more in score whereas 'No' infers number of participants who have not improved 5 points or more in score. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).

Time frame:
At Week 52
Reported as:
Count of participants · Participants
Participants Improving 5 Points or More in KCCQ Clinical Summary Score (Yes/No)
ParticipantsSemaglutide 2.4 mgPlacebo
Yes205149
No76123
SecondaryParticipants Improving 10 Points or More in KCCQ Clinical Summary Score (Yes/No)

Participants improving 10 points or more in KCCQ clinical summary score (Yes/No) at week 52 is presented. The KCCQ is a standardised 23-item, self-administered instrument that quantifies heart failure symptoms (frequency, severity, and recent change), physical limitation, quality of life (QOL), and social limitation. Scores were transformed to a range of 0 to 100 in which higher scores reflected better health status. KCCQ-CSS included the symptom and physical limitation domains of the KCCQ. In reported data, 'Yes' infers number of participants who have improved 10 points or more in score whereas 'No' infers number of participants who have not improved 10 points or more in score. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).

Time frame:
At Week 52
Reported as:
Count of participants · Participants
Participants Improving 10 Points or More in KCCQ Clinical Summary Score (Yes/No)
ParticipantsSemaglutide 2.4 mgPlacebo
Yes163116
No118156
SecondaryChange in KCCQ Overall Summary Score

Change in KCCQ overall summary score from baseline (week 0) to end of treatment (week 52) is presented. The KCCQ is a standardised 23-item, self-administered instrument that quantifies heart failure symptoms (frequency, severity, and recent change), physical limitation, QOL, and social limitation. Scores are transformed to a range of 0 to 100 in which higher scores reflect better health status. KCCQ- overall summary score (OSS) included the symptom, physical limitation, quality of life, and social limitation domains. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).

Time frame:
Baseline (week 0), end of treatment (week 52)
Reported as:
Mean · Score on a scale
Change in KCCQ Overall Summary Score
Score on a scaleSemaglutide 2.4 mgPlacebo
Change in KCCQ Overall Summary Score14.4 ± 18.17.6 ± 18.6
SecondaryParticipants Achieving Threshold for Clinically Meaningful Within-participant Change in KCCQ-CSS (PGI-S)

Participants achieving threshold for clinically meaningful within-participant change (based on participant perspective) in KCCQ-CSS (Patient Global Impression of Status \[PGI-S\]) at week 52 is presented. KCCQ is a standardised 23-item instrument that quantifies heart failure symptoms (frequency, severity, and recent change), physical limitation, QOL, and social limitation. Scores are transformed to a range of 0 to 100 where higher scores reflect better health status. KCCQ-CSS includes the symptom and physical limitation domains of KCCQ. PGI-S for KCCQ was used to rate participants' symptoms of heart failure in last two weeks using a 4-category ordinal scale (no symptoms, mild, moderate, severe). The threshold of 16.3 points is based on PGI-S for KCCQ-CSS. Outcome data was evaluated based on in-trial period. In-trial period was defined as time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).

Time frame:
At Week 52
Reported as:
Count of participants · Participants
Participants Achieving Threshold for Clinically Meaningful Within-participant Change in KCCQ-CSS (PGI-S)
ParticipantsSemaglutide 2.4 mgPlacebo
Participants Achieving Threshold for Clinically Meaningful Within-participant Change in KCCQ-CSS (PGI-S)12083
SecondaryParticipants Achieving Threshold for Clinically Meaningful Within-participant Change in Six Minute Walking Distance (6MWD) (PGI-S)

Participants achieving threshold for clinically meaningful within-participant change in 6MWD (PGI-S) at week 52 is presented. The six minute walk test (6MWT) is a direct and timed measure of walk distance. The goal is for the subject to walk as far as possible in six minutes without running. The PGI-S for 6MWT was used to rate any difficulty that participants were experiencing in walking quickly using a 5-category ordinal scale (not at all difficult, a little difficult, moderately difficult, very difficult, or unable to walk quickly). The threshold of 16.2 meters is based on PGI-S for 6MWT. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).

Time frame:
At Week 52
Reported as:
Count of participants · Participants
Participants Achieving Threshold for Clinically Meaningful Within-participant Change in Six Minute Walking Distance (6MWD) (PGI-S)
ParticipantsSemaglutide 2.4 mgPlacebo
Participants Achieving Threshold for Clinically Meaningful Within-participant Change in Six Minute Walking Distance (6MWD) (PGI-S)148104
SecondaryChange in Waist Circumference

Change in waist circumference from baseline (week 0) to end of treatment (week 52) is presented. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).

Time frame:
From baseline (week 0) to end of treatment (week 52)
Reported as:
Mean · Centimetre (cm)
Change in Waist Circumference
Centimetre (cm)Semaglutide 2.4 mgPlacebo
Change in Waist Circumference-8.9 ± 7.9-2.4 ± 7.2
SecondaryChange in Systolic Blood Pressure

Change in systolic blood pressure from baseline (week -2) to end of treatment (week 52) is presented. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).

Time frame:
Bseline (week -2), end of treatment (week 52)
Reported as:
Mean · Millimetre of mercury (mmHg)
Change in Systolic Blood Pressure
Millimetre of mercury (mmHg)Semaglutide 2.4 mgPlacebo
Change in Systolic Blood Pressure-4.0 ± 16.9-2.9 ± 16.8
SecondaryChange in Glycated Haemoglobin (HbA1c)

Change in HbA1c from baseline (week 0) to end of treatment (week 52) is presented. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).

Time frame:
Baseline (week 0), end of treatment (week 52)
Reported as:
Mean · Percentage of HbA1c
Change in Glycated Haemoglobin (HbA1c)
Percentage of HbA1cSemaglutide 2.4 mgPlacebo
Change in Glycated Haemoglobin (HbA1c)-0.8 ± 1.10.1 ± 0.9
SecondaryNumber of Treatment Emergent Severe or Clinically Significant Hypoglycaemia Episodes

Number of treatment emergent severe or clinically significant hypoglycaemia episodes from baseline (week 0) to end of trial (week 57) is presented. Clinically significant hypoglycemic episode is defined as blood glucose concentration of less than 54 milligrams per deciliter (mg/dL) which is sufficiently low to indicate serious, clinically important hypoglycaemia. Severe hypoglycemic episode is defined as hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery. The outcome data was evaluated based on on-treatment period. A time-point was considered as 'on-treatment' if any dose of trial product had been administered within the prior 5 weeks (35 days).

Time frame:
From baseline (week 0) to end of trial (week 57)
Reported as:
Number · Episodes
Number of Treatment Emergent Severe or Clinically Significant Hypoglycaemia Episodes
EpisodesSemaglutide 2.4 mgPlacebo
Number of Treatment Emergent Severe or Clinically Significant Hypoglycaemia Episodes2030

Adverse events

Collected over From baseline (week 0) to end of trial (week 57). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Semaglutide 2.4 mg6/310 (1.9%)55/310 (17.7%)104/310 (33.5%)
Placebo10/306 (3.3%)88/306 (28.8%)60/306 (19.6%)
Most frequent serious events
Showing 10 of 148
Most frequent serious events
EventSemaglutide 2.4 mgPlacebo
Cardiac failureCardiac disorders4/31022/306
PneumoniaInfections and infestations3/3109/306
Atrial fibrillationCardiac disorders5/3106/306
Acute myocardial infarctionCardiac disorders1/3105/306
Acute kidney injuryRenal and urinary disorders2/3104/306
COVID-19Infections and infestations3/3103/306
Cardiac failure acuteCardiac disorders2/3103/306
Cardiac failure congestiveCardiac disorders2/3103/306
OsteoarthritisMusculoskeletal and connective tissue disorders2/3103/306
Renal failureRenal and urinary disorders0/3103/306
Most frequent other events
Most frequent other events
EventSemaglutide 2.4 mgPlacebo
NauseaGastrointestinal disorders55/31018/306
DiarrhoeaGastrointestinal disorders42/31020/306
COVID-19Infections and infestations26/31031/306
Cardiac failureCardiac disorders13/31030/306
VomitingGastrointestinal disorders26/3107/306
Decreased appetiteMetabolism and nutrition disorders16/31010/306

Baseline characteristics

Full analysis set (FAS) included all randomised participants. 1 eligible participant did not attend the randomisation visit (visit 2) and was randomised in absence by administrative error to placebo; thus, it was decided to exclude the participant from the FAS.

Age, Continuous
Age, Continuous(Years)Semaglutide 2.4 mgPlaceboTotal
Mean68 ± 969 ± 968 ± 9
Sex: Female, Male
Sex: Female, Male(Participants)Semaglutide 2.4 mgPlaceboTotal
Female128145273
Male182161343
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Semaglutide 2.4 mgPlaceboTotal
Hispanic or Latino383876
Not Hispanic or Latino272268540
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Semaglutide 2.4 mgPlaceboTotal
Asian453176
Black or African American13518
White251268519
Other123
Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS)
Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS)(Score on a scale)Semaglutide 2.4 mgPlaceboTotal
Mean58.8 ± 20.356.4 ± 19.757.6 ± 20.0
Body weight
Body weight(Kilograms (kg))Semaglutide 2.4 mgPlaceboTotal
Mean106.4 ± 20.9105.2 ± 21.4105.8 ± 21.1
Six minute walking test
Six minute walking test(Meters (m))Semaglutide 2.4 mgPlaceboTotal
Mean279.7 ± 96.6276.7 ± 93.5278.2 ± 95.0
High Sensitive C-Reactive Protein
High Sensitive C-Reactive Protein(Milligrams per liter (mg/L))Semaglutide 2.4 mgPlaceboTotal
Mean6.7 ± 9.07.2 ± 14.16.9 ± 11.8
08

Study locations

180 sites
  • Eastern Shore Rsrch Inst, LLC
    Fairhope, Alabama 36532, United States
  • Mobile Heart Specialists
    Mobile, Alabama 36608, United States
  • National Heart Institute Cal
    Beverly Hills, California 90211, United States
  • John Muir Physicians Network
    Concord, California 94520, United States
  • Valley Clinical Trials
    Covina, California 91723, United States
  • Keck Medical Center of USC - Outpatient Clinic
    Los Angeles, California 90033, United States
  • Valley Clinical Trials, Inc.
    Northridge, California 91325, United States
  • Lundquist Inst-Biomed Innovtn
    Torrance, California 90502, United States
  • OptumCare Clinical Trials LLC
    Golden, Colorado 80401, United States
  • Excel Med Ctr Clinical Trials
    Boca Raton, Florida 33434, United States
  • Bay Area Cardiology Associates, P.A.
    Brandon, Florida 33511, United States
  • Baptist Heart Specialists_Jacksonville
    Jacksonville, Florida 32258, United States
  • CV Res Ctr of S Florida
    Miami, Florida 33173, United States
  • Endeavor Health Clinical Operations-NCH
    Arlington Heights, Illinois 60005, United States
  • Endeavor Health Glenbook Hosp
    Evanston, Illinois 60201, United States
  • Northwestern University_Chicago_0
    Evanston, Illinois 60208, United States
  • Chicago Medical Research LLC
    Hazel Crest, Illinois 60429, United States
  • Deaconess Specialty Physicians
    Evansville, Indiana 47747, United States
  • Ascension St. Vincent Medical Group
    Indianapolis, Indiana 46260, United States
  • Cardiovascular Rsrch of NW_IN
    Munster, Indiana 46321, United States
  • Cotton-O'Neil Heart Center
    Topeka, Kansas 66606, United States
  • Baptist Health Woodland
    Elizabethtown, Kentucky 42701, United States
  • The Research Group of Lexington LLC
    Lexington, Kentucky 40503, United States
  • Baptist Health Louisville
    Louisville, Kentucky 40207, United States
  • Grace Research, LLC
    Bossier City, Louisiana 71111, United States
  • Heart Clinic of Hammond
    Hammond, Louisiana 70403, United States
  • Clinical Trials of Ame, LLC
    Monroe, Louisiana 71201, United States
  • Grace Research, LLC_Shreveport
    Shreveport, Louisiana 71105, United States
  • Louisiana Heart Center_Slidell
    Slidell, Louisiana 70458, United States
  • Ascension Saint Agnes Heart Ca
    Baltimore, Maryland 21229, United States
  • MedStar Good Samaritan Hosp
    Baltimore, Maryland 21239, United States
  • John Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Elite Research Center
    Flint, Michigan 48532, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Univ of Mississippi Med Ctr
    Jackson, Mississippi 39216, United States
  • Saint Luke's Hospital of Kansas City
    Kansas City, Missouri 64111, United States
  • St Louis Heart & Vascular, P.C.
    St Louis, Missouri 63136, United States
  • Bryan Heart
    Lincoln, Nebraska 68506, United States
  • CHI Health Clinic Cardiology (CUMC - Bergan Mercy)
    Omaha, Nebraska 68124, United States
  • St Francis Hospital Lindner Research Center
    Greenvale, New York 11548, United States
  • NY Presbyt Hosp-W Cornell Med
    New York, New York 10021, United States
  • Carteret Medical Group
    Morehead City, North Carolina 28557, United States
  • Wake Forest Baptist Health
    Winston-Salem, North Carolina 27157, United States
  • Lindner Center,Christ Hospital
    Cincinnati, Ohio 45219, United States
  • Abington Memorial Hospital
    Abington, Pennsylvania 19001, United States
  • Hospital of University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Sanford Health_Sioux Falls
    Sioux Falls, South Dakota 57117, United States
  • Tennessee Center for Clinical Trials
    Tullahoma, Tennessee 37388, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Angio Cardiac Care of Texas
    Houston, Texas 77025, United States
  • Cardiology Consultants of Danville Inc.
    Danville, Virginia 24541, United States
  • Virginia Heart
    Falls Church, Virginia 22042, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23219, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298-5058, United States
  • CEMEDIC
    CABA, Buenos Aires C1440CFD, Argentina
  • CIPREC Arenales
    CABA, C1061AAS., Argentina
  • Centro de Investigación y Prevención Cardiovascular
    CABA, C1119ACN, Argentina
  • CEMEDIC
    CABA, C1440CFD, Argentina
  • Cardiología Palermo Duplicate
    Ciudad Autónoma de Buenos Aire, 1425, Argentina
  • Cardiología Palermo
    Ciudad Autónoma de Buenos Aire, 1425, Argentina
  • Instituto de Cardiología de Corrientes
    Corrientes, W3400AMZ, Argentina
  • Consultorio Integral de Atención al Diabético
    Morón, B1708IFF, Argentina
  • Sanatorio Britanico S.A.
    Rosario, Santa Fe, S2000CVB, Argentina
  • Krankenhaus St. Josef Braunau
    Braunau am Inn, 5280, Austria
  • Medizinische Universität Graz
    Graz, 8036, Austria
  • Medizinische Universität Graz
    Graz, A 8036, Austria
  • Fließer-Görzer [Ordination]
    Saint Stefan, 8511, Austria
  • Medizinische Universität Wien
    Vienna, 1090, Austria
  • Klinik Favoriten
    Vienna, 1100, Austria
  • Imed 19- privat
    Vienna, 1190, Austria
  • AKH Universitätsklinik für Innere Medizin II
    Vienna, A 1090, Austria
  • Universitätsklinik für Innere Medizin II
    Vienna, A 1090, Austria
  • University of Calgary_Calgary
    Calgary, Alberta T2N 4Z6, Canada
  • Univ of Alberta Hosp Edmonton
    Edmonton, Alberta T6G 2B7, Canada
  • North Shore Heart Centre
    North Vancouver, British Columbia V7M 2H4, Canada
  • SMH Cardiology Clinical Trials Inc.
    Surrey, British Columbia V3V 0C6, Canada
  • St. Boniface Hospital
    Winnipeg, Manitoba R2H 2HA6, Canada
  • Cambridge Cardiac Care Centre
    Cambridge, Ontario N1R 6V6, Canada
  • Partnrs Adv Cardio Eval (PACE)
    Newmarket, Ontario L3Y 2P6, Canada
  • Oakville Cardiovascular Research LP
    Oakville, Ontario L6K 3W7, Canada
  • Heart Health Institute Research, Inc.
    Scarborough Village, Ontario M1B 4Z8, Canada
  • Dr. Louis Yao
    Weston, Ontario M9N 1W4, Canada
  • ViaCar Recherche Clinique Inc
    Brossard, Quebec J4Z 2K9, Canada
  • Applied Med Inf Res
    Montreal, Quebec H4A 3T2, Canada
  • Ctr de Med Metab de Lanaudiere
    Terrebonne, Quebec J6X 4P7, Canada
  • Institut universitaire de cardiologie
    Québec, G1V 4G5, Canada
  • Edumed Broumov
    Broumov, 550 01, Czechia
  • Fakultní poliklinika VFN ambulance Srdecniho selhani
    Prague, 120 00, Czechia
  • IKEM
    Prague, 140 21, Czechia
  • MEDICON a.s.
    Prague, 170 00, Czechia
  • Poliklinika Holešovice VISIONARY - Medicon Pharm s.r.o.
    Prague, 170 00, Czechia
  • Charité - Campus Virchow-Klinikum - Kardiologie, Angiologie und Intensivmedizin (CRU)
    Berlin, 13353, Germany
  • Cardiologicum Dresden und Pirna - MVZ "Am Felsenkeller" (Dresden)
    Dresden, 01277, Germany
  • Zentrum für klinische Studien Südbrandenburg GmbH
    Elsterwerda, 04910, Germany
  • MVZ CCB Frankfurt und Main-Taunus GbR
    Frankfurt, 60389, Germany
  • Medical Center - University Of Freiburg
    Freiburg im Breisgau, 79106, Germany
  • Universitätsklinikum Freiburg - Medical Center
    Freiburg im Breisgau, 79106, Germany
  • B. Braun Ambulantes Herzzentrum Kassel MVZ GmbH
    Kassel, 34121, Germany
  • Universitätsklinikum Leipzig - Klinik und Poliklinik für Kardiologie
    Leipzig, 04103, Germany
  • Universitätsmedizin Mainz, Kardiologie I, Studienzentrum
    Mainz, 55131, Germany

Showing the first 100 of 180 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Kosiborod MN, Abildstrom SZ, Borlaug BA, Butler J, Christensen L, Davies M, Hovingh KG, Kitzman DW, Lindegaard ML, Moller DV, Shah SJ, Treppendahl MB, Verma S, Petrie MC. Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype. JACC Heart Fail. 2023 Aug;11(8 Pt 1):1000-1010. doi: 10.1016/j.jchf.2023.05.010. Epub 2023 May 21. PubMed 37294245 ↗
  • Borlaug BA, Kitzman DW, Patel S, Chinnakondepalli KM, Butler J, Davies MJ, Petrie MC, Shah SJ, Verma S, Nunez J, Einfeldt MN, Liisberg K, Salsali A, Kosiborod MN; STEP-HFpEF Trial Committees and Investigators. Semaglutide and Exercise Function in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program. JACC Heart Fail. 2025 Nov;13(11):102660. doi: 10.1016/j.jchf.2025.102660. Epub 2025 Oct 3. PubMed 41045908 ↗
  • Pandey A, Kitzman DW, Chinnakondepalli KM, Patel S, Borlaug BA, Butler J, Davies MJ, Shah SJ, Verma S, Ronnback C, Domdey A, Liisberg K, Schou M, Perna E, Ahmed FZ, Fu M, Petrie MC, Kosiborod MN. Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program. JACC Heart Fail. 2025 Oct;13(10):102610. doi: 10.1016/j.jchf.2025.102610. Epub 2025 Sep 15. PubMed 40956259 ↗
  • Davies MJ, van der Meer P, Verma S, Patel S, Chinnakondepalli KM, Borlaug BA, Butler J, Kitzman DW, Shah SJ, Harring S, Salsali A, Rasmussen S, von Lewinski D, Abhayaratna W, Petrie MC, Kosiborod MN; STEP-HFpEF Trials Committees and Investigators. Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2025 Mar;13(3):196-209. doi: 10.1016/S2213-8587(24)00304-8. Epub 2025 Jan 20. PubMed 39848268 ↗
  • Kosiborod MN, Deanfield J, Pratley R, Borlaug BA, Butler J, Davies MJ, Emerson SS, Kahn SE, Kitzman DW, Lingvay I, Mahaffey KW, Petrie MC, Plutzky J, Rasmussen S, Ronnback C, Shah SJ, Verma S, Weeke PE, Lincoff AM; SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM Trial Committees and Investigators. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet. 2024 Sep 7;404(10456):949-961. doi: 10.1016/S0140-6736(24)01643-X. Epub 2024 Aug 30. PubMed 39222642 ↗
  • Solomon SD, Ostrominski JW, Wang X, Shah SJ, Borlaug BA, Butler J, Davies MJ, Kitzman DW, Verma S, Abildstrom SZ, Nygaard Einfeldt M, Rasmussen S, Abhayaratna WP, Ahmed FZ, Ben-Gal T, Chopra V, Ito H, Merkely B, Nunez J, Senni M, van der Meer P, Wolf D, Petrie MC, Kosiborod MN; STEP-HFpEF Trial Committees and Investigators. Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure. J Am Coll Cardiol. 2024 Oct 22;84(17):1587-1602. doi: 10.1016/j.jacc.2024.08.021. Epub 2024 Aug 30. PubMed 39217567 ↗
  • Verma S, Butler J, Borlaug BA, Davies MJ, Kitzman DW, Petrie MC, Shah SJ, Jensen TJ, Rasmussen S, Ronnback C, Merkely B, O'Keefe E, Kosiborod MN; STEP-HFpEF and STEP-HFpEF DM Investigators. Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Program. J Am Coll Cardiol. 2024 Oct 22;84(17):1603-1614. doi: 10.1016/j.jacc.2024.08.023. Epub 2024 Aug 30. PubMed 39217565 ↗
  • Verma S, Petrie MC, Borlaug BA, Butler J, Davies MJ, Kitzman DW, Shah SJ, Ronnback C, Abildstrom SZ, Liisberg K, Wolf D, von Lewinski D, Lelonek M, Melenovsky V, Senni M, Kosiborod MN; STEP-HFpEF Trial Committees and Investigators. Inflammation in Obesity-Related HFpEF: The STEP-HFpEF Program. J Am Coll Cardiol. 2024 Oct 22;84(17):1646-1662. doi: 10.1016/j.jacc.2024.08.028. Epub 2024 Aug 30. PubMed 39217564 ↗
  • Schou M, Petrie MC, Borlaug BA, Butler J, Davies MJ, Kitzman DW, Shah SJ, Verma S, Patel S, Chinnakondepalli KM, Harring S, Abildstrom SZ, Liisberg K, Kosiborod MN; STEP-HFpEF Trial Committees and Investigators. Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Program. J Am Coll Cardiol. 2024 Jul 16;84(3):247-257. doi: 10.1016/j.jacc.2024.04.038. Epub 2024 Jun 23. PubMed 38913004 ↗
  • Verma S, Butler J, Borlaug BA, Davies M, Kitzman DW, Shah SJ, Petrie MC, Barros E, Ronnback C, Vestergaard LS, Schou M, Ezekowitz JA, Sharma K, Patel S, Chinnakondepalli KM, Kosiborod MN; STEP-HFpEF Trial Committees and Investigators. Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials. J Am Coll Cardiol. 2024 Aug 27;84(9):773-785. doi: 10.1016/j.jacc.2024.06.001. Epub 2024 Jun 23. PubMed 38913003 ↗
  • Shah SJ, Sharma K, Borlaug BA, Butler J, Davies M, Kitzman DW, Petrie MC, Verma S, Patel S, Chinnakondepalli KM, Einfeldt MN, Jensen TJ, Rasmussen S, Asleh R, Ben-Gal T, Kosiborod MN. Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials. Eur Heart J. 2024 Sep 14;45(35):3254-3269. doi: 10.1093/eurheartj/ehae322. PubMed 38739118 ↗
  • Butler J, Shah SJ, Petrie MC, Borlaug BA, Abildstrom SZ, Davies MJ, Hovingh GK, Kitzman DW, Moller DV, Verma S, Einfeldt MN, Lindegaard ML, Rasmussen S, Abhayaratna W, Ahmed FZ, Ben-Gal T, Chopra V, Ezekowitz JA, Fu M, Ito H, Lelonek M, Melenovsky V, Merkely B, Nunez J, Perna E, Schou M, Senni M, Sharma K, van der Meer P, Von Lewinski D, Wolf D, Kosiborod MN; STEP-HFpEF Trial Committees and Investigators. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet. 2024 Apr 27;403(10437):1635-1648. doi: 10.1016/S0140-6736(24)00469-0. Epub 2024 Apr 7. PubMed 38599221 ↗
  • Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, Kitzman DW, Moller DV, Treppendahl MB, Verma S, Jensen TJ, Liisberg K, Lindegaard ML, Abhayaratna W, Ahmed FZ, Ben-Gal T, Chopra V, Ezekowitz JA, Fu M, Ito H, Lelonek M, Melenovsky V, Merkely B, Nunez J, Perna E, Schou M, Senni M, Sharma K, van der Meer P, Von Lewinski D, Wolf D, Shah SJ; STEP-HFpEF DM Trial Committees and Investigators. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. N Engl J Med. 2024 Apr 18;390(15):1394-1407. doi: 10.1056/NEJMoa2313917. Epub 2024 Apr 6. PubMed 38587233 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Oct 2023, 27 months.

Results were first posted in Nov 2026, 3 years after primary completion. A results delay was requested in Oct 2024.

Of 167 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 23. This study's 27 months is above that.

Counting every sponsor, half of 230 studies reached it within 19 months; a quarter within 13 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2021
First posted
Jun 7, 2021
StartActual
Jun 15, 2021
Primary completionActual
Oct 11, 2023
CompletionActual
Oct 11, 2023
Results delay requested
Oct 8, 2024
Results first posted
Nov 2, 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 2, 2026
Sites
16 sites added, 16 sites removed
Show 16 added (4 Netherlands, 2 Japan, 2 Poland, 2 Sweden, 1 United States, 1 Argentina, 1 Germany, 1 India, 1 Israel, 1 Italy)
  • OptumCare Clinical Trials LLC · Golden, United States
  • CIPREC Arenales · CABA, Argentina
  • Zentrum für klinische Studien Südbrandenburg GmbH · Elsterwerda, Germany
  • Marengo Asia Health Care Private Limited · Ahmedabad, India
  • Sheba MC - Cardiology Clinical Research Unit · Tel HaShomer, Israel
  • Azienda Ospedaliera di Padova · Padova, Italy
  • Omihachiman Community Medical Center_Cardiovascular Medicine · Omihachiman-shi, Siga, Japan
  • Osaka City General Hospital · Osaka, Japan
  • Gelre Zkh Apeldoorn · Apeldoorn, Netherlands
  • Rode Kruis Zkh Beverwijk · Beverwijk, Netherlands
  • Saxenburgh MC - Cardiologie · Hardenberg, Netherlands
  • Bravis Zkh Roosendaal · Roosendaal, Netherlands
  • Ind. Spec. Prak. Lek. w dziedz. Kardiologii lek. med. K. Cymerman · Gdynia, Poland
  • Uniwersytecki Szpital Kliniczny nr 2 Uniwersytetu Medycznego w Lodzi · Lodz, Poland
  • Sahlgrenska US - Medicinkliniken · Gothenburg, Sweden
  • Uppsala US - Hjärtmottagningen · Uppsala, Sweden
Show 16 removed
  • New West Physicians,Inc. · Golden, United States
  • Centro de Investigación y Prevención Cardiovascular · CABA, Argentina
  • Zentrum fuer klinische Studien Suedbrandenburg GmbH · Elsterwerda, Germany
  • CIMS- Care Institute of Medical Sciences · Ahmedabad, India
  • Sheba MC - Cardiology Clinical Research Unit · Tel Litwinsky, Israel
  • Azienda Ospedaliera di Padova - MASTER · Padova, Italy
  • Omihachiman Community Medical Center_Omihachiman-shi, Siga · Omihachiman-shi, Siga, Japan
  • Osaka City General Hospital_Endocrinology and Diabetes Mellitus · Osaka, Japan
  • Gelre Ziekenhuizen Apeldoorn · Apeldoorn, Netherlands
  • Rode Kruis Ziekenhuis Beverwijk · Beverwijk, Netherlands
  • Saxenburgh Medisch Centrum · Hardenberg, Netherlands
  • Bravis Ziekenhuis · Roosendaal, Netherlands
  • Ind. Prak. Lek. w dziedz. Kardiologii lek. med. K. Cymerman · Gdynia, Poland
  • Uniwersytecki Szpital Kliniczny nr 2 Uniwersytetu Medycznego w Łodzi · Lodz, Poland
  • Dept of Med Sahlgrenska/Östra · Gothenburg, Sweden
  • Hjärtmottagningen · Uppsala, Sweden
Nov 2, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedChange in KCCQ (Kansas City Cardiomyopathy Questionnaire) clinical summary scoreClinical Summary ScoreTime frame: From baseline (week 0) to end of treatment (week 52) → Baseline (week 0), end of treatment (week 52)
  • EditedPercentage Change in body weightBody WeightTime frame: From baseline (week 0) to end of treatment (week 52) → Baseline (week 0), end of treatment (week 52)
Nov 2, 2026
Documents
Secondary outcomes
13 edited, 1 added, 7 removed, 1 description edited
What changed in the outcomes
  • EditedChange in 6Six-minute walking distanceWalking DistanceTime frame: From baseline (week 0) to end of treatment (week 52) → Baseline (week 0), end of treatment (week 52)
  • EditedParticipant achievingParticipants Achieving 10% weight lossWeight Loss or moreMore (Yes/No)Time frame: From baseline (week 0) to end of treatment (week 52) → At Week 52
  • EditedParticipant achievingParticipants Achieving 15% weight lossWeight Loss or moreMore (Yes/No)Time frame: From baseline (week 0) to end of treatment (week 52) → At Week 52
  • EditedParticipant achievingParticipants Achieving 20% weight lossWeight Loss or moreMore (Yes/No)Time frame: From baseline (week 0) to end of treatment (week 52) → At Week 52
  • EditedParticipant improvingParticipants Improving 5 pointsPoints or moreMore in KCCQ clinical summary scoreClinical Summary Score (Yes/No)Time frame: From baseline (week 0) to end of treatment (week 52) → At Week 52
  • EditedParticipant improvingParticipants Improving 10 pointsPoints or moreMore in KCCQ clinical summary scoreClinical Summary Score (Yes/No)Time frame: From baseline (week 0) to end of treatment (week 52) → At Week 52
  • EditedChange in KCCQ overall summary scoreOverall Summary ScoreTime frame: From baseline (week 0) to end of treatment (week 52) → Baseline (week 0), end of treatment (week 52)
  • EditedParticipant achieving thresholdParticipants Achieving Threshold for clinically meaningful withinClinically Meaningful Within-subject changeparticipant Change in KCCQ-CSS (PGI-S)Time frame: From baseline (week 0) to end of treatment (week 52) → At Week 52
  • EditedParticipant achieving thresholdParticipants Achieving Threshold for clinically meaningful withinClinically Meaningful Within-subject changeparticipant Change in Six Minute Walking Distance (6MWD) (PGI-S)Time frame: From baseline (week 0) to end of treatment (week 52) → At Week 52
  • EditedChange in waist circumferenceWaist CircumferenceTime frame: From baseline (week 0) to end of treatment (visit 52) → From baseline (week 0) to end of treatment (week 52)
  • EditedChange in systolic blood pressureSystolic Blood PressureTime frame: From baseline (week -2) to end of treatment (week 52) → Bseline (week -2), end of treatment (week 52)
  • EditedChange in glycated haemoglobinGlycated Haemoglobin (HbA1c)Time frame: From baseline (week 0) to end of treatment (week 52) → Baseline (week 0), end of treatment (week 52)
  • EditedNumber of treatment emergent severeTreatment Emergent Severe or clinically significant hypoglycaemia episodesClinically Significant Hypoglycaemia EpisodesTime frame: From baseline (week 0) to end of trial (week 57)
  • AddedHierarchical Composite Endpoint: Total Number of Wins for Each Treatment GroupTime frame: Baseline (week 0), end of trial (week 57)
  • RemovedHierarchical composite of time to all-cause deathTime frame: From baseline (week 0) to end of study (week 57)
  • RemovedHierarchical composite of number of heart failure events requiring hospitalisation or urgent heart failure visitTime frame: From baseline (week 0) to end of study (week 57)
  • RemovedHierarchical composite of time to first heart failure event requiring hospitalisation or urgent heart failure visitTime frame: From baseline (week 0) to end of study (week 57)
  • RemovedHierarchical composite of difference at least 15 inKansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score change from baseline to 52 weeksTime frame: From baseline (week 0) to end of study (week 57)
  • RemovedHierarchical composite of difference at least 10 in KCCQ clinical summary score change from baseline to 52 weeksTime frame: From baseline (week 0) to end of study (week 57)
  • RemovedHierarchical composite of difference at least 5 in KCCQ clinical summary score change from baseline to 52 weeksTime frame: From baseline (week 0) to end of study (week 57)
  • RemovedHierarchical composite of difference at least 30 metres in six-minute walking distance change from baseline to 52 weeks (assessed by the win ratio)Time frame: From baseline (week 0) to end of study (week 57)
  • DescriptionChange in C-Reactive Protein: how it is measured was reworded
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Results posted
    16 sites added, 16 sites removed
    Show 16 added (4 Netherlands, 2 Japan, 2 Poland, 2 Sweden, 1 United States, 1 Argentina, 1 Germany, 1 India, 1 Israel, 1 Italy)
    • OptumCare Clinical Trials LLC · Golden, United States
    • CIPREC Arenales · CABA, Argentina
    • Zentrum für klinische Studien Südbrandenburg GmbH · Elsterwerda, Germany
    • Marengo Asia Health Care Private Limited · Ahmedabad, India
    • Sheba MC - Cardiology Clinical Research Unit · Tel HaShomer, Israel
    • Azienda Ospedaliera di Padova · Padova, Italy
    • Omihachiman Community Medical Center_Cardiovascular Medicine · Omihachiman-shi, Siga, Japan
    • Osaka City General Hospital · Osaka, Japan
    • Gelre Zkh Apeldoorn · Apeldoorn, Netherlands
    • Rode Kruis Zkh Beverwijk · Beverwijk, Netherlands
    • Saxenburgh MC - Cardiologie · Hardenberg, Netherlands
    • Bravis Zkh Roosendaal · Roosendaal, Netherlands
    • Ind. Spec. Prak. Lek. w dziedz. Kardiologii lek. med. K. Cymerman · Gdynia, Poland
    • Uniwersytecki Szpital Kliniczny nr 2 Uniwersytetu Medycznego w Lodzi · Lodz, Poland
    • Sahlgrenska US - Medicinkliniken · Gothenburg, Sweden
    • Uppsala US - Hjärtmottagningen · Uppsala, Sweden
    Show 16 removed
    • New West Physicians,Inc. · Golden, United States
    • Centro de Investigación y Prevención Cardiovascular · CABA, Argentina
    • Zentrum fuer klinische Studien Suedbrandenburg GmbH · Elsterwerda, Germany
    • CIMS- Care Institute of Medical Sciences · Ahmedabad, India
    • Sheba MC - Cardiology Clinical Research Unit · Tel Litwinsky, Israel
    • Azienda Ospedaliera di Padova - MASTER · Padova, Italy
    • Omihachiman Community Medical Center_Omihachiman-shi, Siga · Omihachiman-shi, Siga, Japan
    • Osaka City General Hospital_Endocrinology and Diabetes Mellitus · Osaka, Japan
    • Gelre Ziekenhuizen Apeldoorn · Apeldoorn, Netherlands
    • Rode Kruis Ziekenhuis Beverwijk · Beverwijk, Netherlands
    • Saxenburgh Medisch Centrum · Hardenberg, Netherlands
    • Bravis Ziekenhuis · Roosendaal, Netherlands
    • Ind. Prak. Lek. w dziedz. Kardiologii lek. med. K. Cymerman · Gdynia, Poland
    • Uniwersytecki Szpital Kliniczny nr 2 Uniwersytetu Medycznego w Łodzi · Lodz, Poland
    • Dept of Med Sahlgrenska/Östra · Gothenburg, Sweden
    • Hjärtmottagningen · Uppsala, Sweden
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedChange in KCCQ (Kansas City Cardiomyopathy Questionnaire) clinical summary scoreClinical Summary ScoreTime frame: From baseline (week 0) to end of treatment (week 52) → Baseline (week 0), end of treatment (week 52)
    • EditedPercentage Change in body weightBody WeightTime frame: From baseline (week 0) to end of treatment (week 52) → Baseline (week 0), end of treatment (week 52)
    Secondary outcomes 13 edited, 1 added, 7 removed, 1 description edited
    What changed in the outcomes
    • EditedChange in 6Six-minute walking distanceWalking DistanceTime frame: From baseline (week 0) to end of treatment (week 52) → Baseline (week 0), end of treatment (week 52)
    • EditedParticipant achievingParticipants Achieving 10% weight lossWeight Loss or moreMore (Yes/No)Time frame: From baseline (week 0) to end of treatment (week 52) → At Week 52
    • EditedParticipant achievingParticipants Achieving 15% weight lossWeight Loss or moreMore (Yes/No)Time frame: From baseline (week 0) to end of treatment (week 52) → At Week 52
    • EditedParticipant achievingParticipants Achieving 20% weight lossWeight Loss or moreMore (Yes/No)Time frame: From baseline (week 0) to end of treatment (week 52) → At Week 52
    • EditedParticipant improvingParticipants Improving 5 pointsPoints or moreMore in KCCQ clinical summary scoreClinical Summary Score (Yes/No)Time frame: From baseline (week 0) to end of treatment (week 52) → At Week 52
    • EditedParticipant improvingParticipants Improving 10 pointsPoints or moreMore in KCCQ clinical summary scoreClinical Summary Score (Yes/No)Time frame: From baseline (week 0) to end of treatment (week 52) → At Week 52
    • EditedChange in KCCQ overall summary scoreOverall Summary ScoreTime frame: From baseline (week 0) to end of treatment (week 52) → Baseline (week 0), end of treatment (week 52)
    • EditedParticipant achieving thresholdParticipants Achieving Threshold for clinically meaningful withinClinically Meaningful Within-subject changeparticipant Change in KCCQ-CSS (PGI-S)Time frame: From baseline (week 0) to end of treatment (week 52) → At Week 52
    • EditedParticipant achieving thresholdParticipants Achieving Threshold for clinically meaningful withinClinically Meaningful Within-subject changeparticipant Change in Six Minute Walking Distance (6MWD) (PGI-S)Time frame: From baseline (week 0) to end of treatment (week 52) → At Week 52
    • EditedChange in waist circumferenceWaist CircumferenceTime frame: From baseline (week 0) to end of treatment (visit 52) → From baseline (week 0) to end of treatment (week 52)
    • EditedChange in systolic blood pressureSystolic Blood PressureTime frame: From baseline (week -2) to end of treatment (week 52) → Bseline (week -2), end of treatment (week 52)
    • EditedChange in glycated haemoglobinGlycated Haemoglobin (HbA1c)Time frame: From baseline (week 0) to end of treatment (week 52) → Baseline (week 0), end of treatment (week 52)
    • EditedNumber of treatment emergent severeTreatment Emergent Severe or clinically significant hypoglycaemia episodesClinically Significant Hypoglycaemia EpisodesTime frame: From baseline (week 0) to end of trial (week 57)
    • AddedHierarchical Composite Endpoint: Total Number of Wins for Each Treatment GroupTime frame: Baseline (week 0), end of trial (week 57)
    • RemovedHierarchical composite of time to all-cause deathTime frame: From baseline (week 0) to end of study (week 57)
    • RemovedHierarchical composite of number of heart failure events requiring hospitalisation or urgent heart failure visitTime frame: From baseline (week 0) to end of study (week 57)
    • RemovedHierarchical composite of time to first heart failure event requiring hospitalisation or urgent heart failure visitTime frame: From baseline (week 0) to end of study (week 57)
    • RemovedHierarchical composite of difference at least 15 inKansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score change from baseline to 52 weeksTime frame: From baseline (week 0) to end of study (week 57)
    • RemovedHierarchical composite of difference at least 10 in KCCQ clinical summary score change from baseline to 52 weeksTime frame: From baseline (week 0) to end of study (week 57)
    • RemovedHierarchical composite of difference at least 5 in KCCQ clinical summary score change from baseline to 52 weeksTime frame: From baseline (week 0) to end of study (week 57)
    • RemovedHierarchical composite of difference at least 30 metres in six-minute walking distance change from baseline to 52 weeks (assessed by the win ratio)Time frame: From baseline (week 0) to end of study (week 57)
    • DescriptionChange in C-Reactive Protein: how it is measured was reworded
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04916470
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jun 7, 2021
Start date
Jun 15, 2021
Primary completion
Oct 11, 2023
Completion
Oct 11, 2023
Results posted
Nov 2, 2026
Last update
Nov 2, 2026

Study contacts

Clinical Transparency (Dept.1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion